1. Home
  2. FLEX vs NTRA Comparison

FLEX vs NTRA Comparison

Compare FLEX & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flex Ltd.

FLEX

Flex Ltd.

HOLD

Current Price

$106.85

Market Cap

43.9B

Sector

Technology

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$328.79

Market Cap

45.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLEX
NTRA
Founded
1990
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
43.9B
45.3B
IPO Year
1997
2015

Fundamental Metrics

Financial Performance
Metric
FLEX
NTRA
Price
$106.85
$328.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
15
Target Price
$66.89
$259.07
AVG Volume (30 Days)
4.3M
1.4M
Earning Date
05-06-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
10.43
0.65
EPS
0.76
N/A
Revenue
$28,679,925,000.00
$210,939,000.00
Revenue This Year
$8.14
$18.08
Revenue Next Year
$6.28
$19.65
P/E Ratio
$145.33
N/A
Revenue Growth
18.95
N/A
52 Week Low
$51.76
$157.43
52 Week High
$166.86
$333.56

Technical Indicators

Market Signals
Indicator
FLEX
NTRA
Relative Strength Index (RSI) 36.39 68.06
Support Level $58.59 $187.64
Resistance Level $131.66 N/A
Average True Range (ATR) 5.59 10.93
MACD -0.91 1.95
Stochastic Oscillator 9.17 90.53

Price Performance

Historical Comparison
FLEX
NTRA

About FLEX Flex Ltd.

Flex Ltd is the developed, end-to-end manufacturing partner of choice that helps a diverse customer base design, build, deliver and manage products that improve the world. The Company's full suite of specialized capabilities includes design and engineering, supply chain, manufacturing, and integrated services, plus a portfolio of power and cooling products. Its reportable segments includes Integrated Technology Solutions, Regulated Manufacturing Solutions, and Cloud and Power Infrastructure.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: